Evidence map›Paper›PMID 30971397›Full record

ReviewBlood advances2019

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.

Julia Bohlius, Kari Bohlke, Roberto Castelli, Benjamin Djulbegovic, Maryam B Lustberg, Massimo Martino, Giannis Mountzios, Namrata Peswani, Laura Porter, Tiffany N Tanaka and 3 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. MASCC/ISOO Clinical Practice Statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Randomized trial of sucrosomial iron supplementation in patients with chemotherapy-related anemia treated with ESA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 13 institutions in 5 countries.

Julia BohliusUniversity of Bern, Bern, Switzerland.
Kari BohlkeAmerican Society of Clinical Oncology, Alexandria, VA.
Roberto CastelliUniversity of Milan, Milan, Italy.
Benjamin DjulbegovicCity of Hope, Duarte, CA.
Maryam B LustbergOhio State University, Columbus, OH.
Massimo MartinoAzienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Giannis MountziosHenry Dunant Hospital Center, Athens, Greece.
Namrata PeswaniAdvocate Medical Group, Orland Park, IL.
Laura PorterIndependent Patient Advocate, Washington, DC.
Tiffany N TanakaUC San Diego Moores Cancer Center, La Jolla, CA.
Gianluca TrifiròUniversity of Messina, Messina, Italy.
Hushan YangThomas Jefferson University, Philadelphia, PA; and.
Alejandro Lazo-LangnerWestern University, London, ON, Canada.
Advocate Health Care · USAmerican Society of Clinical Oncology · USAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITCity of Hope · USHenry Dunant Hospital · GRMoores Cancer CenterPatient Advocate Foundation · USThe Ohio State University · USThomas Jefferson University · USUniversity of Bern · CHUniversity of Messina · ITUniversity of Milan · ITWestern University · CA

Funding

A population-based approach to single CTC analysis in metastatic breast cancer outcomeR01CA207468 · NCI · THOMAS JEFFERSON UNIVERSITY · PI YANG, HUSHAN · 2017 to 2022
$2.7M
NCI NIH HHS R01 CA207468
6 · The paper itself

Abstract

purposeTo update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.

methodsPubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ESAs, the literature search was expanded to include meta-analyses and RCTs in patients with cancer or chronic kidney disease and cohort studies in patients with cancer due to limited RCT evidence in the cancer setting. ASCO and ASH convened an Expert Panel to review the evidence and revise previous recommendations as needed.

resultsThe primary literature review included 15 meta-analyses of RCTs and two RCTs. A growing body of evidence suggests that adding iron to treatment with an ESA may improve hematopoietic response and reduce the likelihood of RBC transfusion. The biosimilar literature review suggested that biosimilars of epoetin alfa have similar efficacy and safety to reference products, although evidence in cancer remains limited. RECOMMENDATIONS: ESAs (including biosimilars) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin has declined to < 10 g/dL. RBC transfusion is also an option. With the exception of selected patients with myelodysplastic syndromes, ESAs should not be offered to most patients with nonchemotherapy-associated anemia. During ESA treatment, hemoglobin may be increased to the lowest concentration needed to avoid transfusions. Iron replacement may be used to improve hemoglobin response and reduce RBC transfusions for patients receiving ESA with or without iron deficiency. Additional information is available at www.asco.org/supportive-care-guidelines and www.hematology.org/guidelines.

Indexed as

AnemiaBiosimilar PharmaceuticalsHematinicsHematologyHumansNeoplasmsPractice Guidelines as TopicSocieties, MedicalUnited StatesBiosimilar PharmaceuticalsHematinics

Identifiers

PMID30971397
PMCPMC6482353
OpenAlexW2948352962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.